A higher correlation of HCV core antigen with CD4+ T cell counts compared with HCV RNA in HCV/HIV-1 coinfected patients

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Shen, Tao ^a   Chen, Xiangmei ^a   Zhang, Weidong ^b   Xi, Yuanlin ^b   Cao, Guanghua ^c   Zhi, Yuhong ^d   Wang, Shuiwang ^d   Xu, Chunhui ^a   Wei, Lai ^e   Lu, Fengmin ^a   Zhuang, Hui ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b ZHENGZHOU UNIVERSITY   (China)

^c Shangcai County People's Hospital   (China)

^d Shangcai Center for Disease Control and Prevention   (China)

^e PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEPATITIS C ANTIBODY; HEPATITIS C ANTIGEN; VIRUS RNA; CORE PROTEIN; NUCLEOCAPSID PROTEIN, HEPATITIS C VIRUS; VIRUS ANTIGEN;

ANTIGEN DETECTION; ARTICLE; BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CHINA; CONTROLLED STUDY; CORRELATIONAL STUDY; CROSS-SECTIONAL STUDY; HEPATITIS C; HEPATITIS C VIRUS; HOST RESISTANCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MIXED INFECTION; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; VIRUS LOAD; VIRUS REPLICATION; ADULT; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETICS; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MALE; MIDDLE AGED; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIROLOGY;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; ALANINE TRANSAMINASE; ANTIGENS, VIRAL; ASPARTATE AMINOTRANSFERASES; CD4 LYMPHOCYTE COUNT; CHINA; COINFECTION; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; VIRAL CORE PROTEINS; VIRAL LOAD;

EID: 80051647478     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023550     Document Type: Article

References (35)

1. Wu Z, Liu Z, Detels R, (1995) HIV-1 infection in commercial plasma donors in China. Lancet 346: 61-62.
2. Wu Z, Rou K, Detels R, (2001) Prevalence of HIV infection among former commercial plasma donors in rural eastern China. Health Policy Plan 16: 41-46.
3. Zhang L, Chen Z, Cao Y, Yu J, Li G, et al. (2004) Molecular characterization of human immunodeficiency virus type 1 and hepatitis C virus in paid blood donors and injection drug users in china. J Virol 78: 13591-13599.
4. Thomas DL, Zenilman JM, Alter HJ, Shih JW, Galai N, et al. (1995) Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore--an analysis of 309 sex partnerships. J Infect Dis 171: 768-775.
5. Thomas DL, (2002) Hepatitis C and human immunodeficiency virus infection. Hepatology 36: S201-209.
6. Rockstroh JK, Ewig S, Bauer T, Luchters G, Oldenburg J, et al. (1995) Male-to-female transmission of HIV in a cohort of hemophiliacs--frequency, risk factors and effect of sexual counseling. Infection 23: 29-32.
7. Dienstag JL, (1997) Sexual and perinatal transmission of hepatitis C. Hepatology 26: 66S-70S.
8. Conry-Cantilena C, VanRaden M, Gibble J, Melpolder J, Shakil AO, et al. (1996) Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 334: 1691-1696.
9. Kenny-Walsh E, (1999) Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 340: 1228-1233.
10. Muller R, (1996) The natural history of hepatitis C: clinical experiences. J Hepatol 24: 52-54.
11. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, et al. (1999) The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341: 556-562.
12. Messick K, Sanders JC, Goedert JJ, Eyster ME, (2001) Hepatitis C viral clearance and antibody reactivity patterns in persons with haemophilia and other congenital bleeding disorders. Haemophilia 7: 568-574.
13. Vogt M, Lang T, Frosner G, Klingler C, Sendl AF, et al. (1999) Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 341: 866-870.
14. Seeff LB, Miller RN, Rabkin CS, Buskell-Bales Z, Straley-Eason KD, et al. (2000) 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 132: 105-111.
15. Uto H, Stuver SO, Hayashi K, Kumagai K, Sasaki F, et al. (2009) Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort study. Hepatology 50: 393-399.
16. Valdez H, Anthony D, Farukhi F, Patki A, Salkowitz J, et al. (2000) Immune responses to hepatitis C and non-hepatitis C antigens in hepatitis C virus infected and HIV-1 coinfected patients. AIDS 14: 2239-2246.
17. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853-860.
18. Collaboration TATC, (2008) Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 372: 293-299.
19. Bica I, McGovern B, Dhar R, Stone D, McGowan K, et al. (2001) Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 32: 492-497.
20. Monga HK, Rodriguez-Barradas MC, Breaux K, Khattak K, Troisi CL, et al. (2001) Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 33: 240-247.
21. Busch MP, Glynn SA, Stramer SL, Orland J, Murphy EL, et al. (2006) Correlates of hepatitis C virus (HCV) RNA negativity among HCV-seropositive blood donors. Transfusion 46: 469-475.
22. Lee PL, Wang JH, Tung HD, Lee CM, Lu SN, (2004) A higher than expected recovery rate from hepatitis C infection amongst adolescents: a community study in a hepatitis C-endemic township in Taiwan. Trans R Soc Trop Med Hyg 98: 367-372.
23. Maida I, Nunez M, Rios MJ, Martin-Carbonero L, Sotgiu G, et al. (2006) Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr 42: 177-182.
24. Merchante N, Perez-Camacho I, Mira JA, Rivero A, Macias J, et al. (2010) Prevalence and risk factors for abnormal liver stiffness in HIV-infected patients without viral hepatitis coinfection: role of didanosine. Antivir Ther 15: 753-763.
25. Sterling RK, Chiu S, Snider K, Nixon D, (2008) The prevalence and risk factors for abnormal liver enzymes in HIV-positive patients without hepatitis B or C coinfections. Dig Dis Sci 53: 1375-1382.
26. Kovari H, Ledergerber B, Battegay M, Rauch A, Hirschel B, et al. (2010) Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection. Clin Infect Dis 50: 502-511.
27. Ingiliz P, Valantin MA, Duvivier C, Medja F, Dominguez S, et al. (2009) Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology 49: 436-442.
28. Carr A, Cooper DA, (2000) Adverse effects of antiretroviral therapy. Lancet 356: 1423-1430.
29. van Leth F, Andrews S, Grinsztejn B, Wilkins E, Lazanas MK, et al. (2005) The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS 19: 463-471.
30. Takahashi M, Saito H, Higashimoto M, Atsukawa K, Ishii H, (2005) Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy. J Clin Microbiol 43: 186-191.
31. Bouvier-Alias M, Patel K, Dahari H, Beaucourt S, Larderie P, et al. (2002) Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. Hepatology 36: 211-218.
32. Aoyagi K, Ohue C, Iida K, Kimura T, Tanaka E, et al. (1999) Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen. J Clin Microbiol 37: 1802-1808.
33. Gerlich WHVA, (2010) Highly sensitive assay for hepatitis C virus core antigen. Gastroenterology and Hepatology Insights. Report of an expert meeting on its evaluation and clinical significance.
34. Nakamuta M, Shimohashi N, Tada S, Kinukawa N, Enjoji M, et al. (2001) Serum levels of HCV RNA and core protein before and after incubation at 37 degrees C for 24 h. Hepatol Res 19: 254-262.
35. Tanaka Y, Takagi K, Fujihara T, Kitsugi K, Fujiwara K, et al. (2003) High stability of enzyme immunoassay for hepatitis C virus core antigen-evaluation before and after incubation at room temperature. Hepatol Res 26: 261-267.